The present invention provides novel ryanodine receptor type 2 (RyR2) inhibitors and methods of their use in the treatment of cardiac conditions. In general, the RyR2 inhibitors of the present invention assist in the normalization of intracellular calcium homeostasis. In certain embodiments, the RyR2 inhibitors are store-overload-induced Ca
2+
release (SOICR) inhibitors that minimally inhibit or do not inhibit Ca
2+
-induced Ca
2+
release (CICR), thereby providing beneficial effects in cardiac therapy.
本发明提供了新颖的Ryanodine受体类型2(RyR2)
抑制剂及其在治疗心脏疾病中的使用方法。一般而言,本发明的RyR2
抑制剂有助于使细胞内
钙离子稳态正常化。在某些实施例中,RyR2
抑制剂是储存超载诱导的Ca2+释放(SOICR)
抑制剂,最小程度地抑制或不抑制Ca2+诱导的Ca2+释放(CICR),从而在心脏治疗中提供有益效果。